Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes
Open Access
- 1 January 2014
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 5 (1), 40-51
- https://doi.org/10.4239/wjd.v5.i1.40
Abstract
There are many advantages of combining incretin therapy [glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] with insulin therapy as a glucose-lowering strategy in type 2 diabetes. One important advantage is the complementary mode of the mechanistic action of incretin and insulin therapy. Another advantage is the reduction in risk of hypoglycemia and weight gain when adding incretin therapy to insulin. Several clinical trials have studied the addition of GLP-1 receptor agonists [exenatide BID (twice daily), lixisenatide, albiglutide] or DPP-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin) to ongoing insulin therapy or adding insulin to ongoing therapy with a GLP-1 receptor agonist (liraglutide). These studies show improved glycemia in the presence of limited risk for hypoglycemia and weight gain with the combination of incretin therapy with insulin. This article reviews the background and clinical studies on this combination.Keywords
This publication has 78 references indexed in Scilit:
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 2013
- Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemiaRegulatory Peptides, 2013
- Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetesVascular Health and Risk Management, 2013
- Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysisDiabetes, Obesity and Metabolism, 2012
- Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysisDiabetes, Obesity and Metabolism, 2011
- New Perspectives in Type 2 Diabetes, Cardiovascular Risk, and Treatment GoalsPostgraduate Medicine, 2010
- The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin AloneDiabetes Care, 2009
- Mechanisms of action of glucagon-like peptide 1 in the pancreasPharmacology & Therapeutics, 2006
- Alpha cell function in health and disease: influence of glucagon-like peptide-1Diabetologia, 2005
- Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humansAmerican Journal of Physiology-Endocrinology and Metabolism, 1997